*Please allow 4-6 weeks to process your CME and MOC certificates.*

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, and nurse practitioners involved in the care of patients with chronic liver disease.


Statement of Need 

The goal of this program is to provide important clinical and scientific data on the management of chronic liver disease.


Educational Objectives

Upon completion of this symposium, participants should be better able to:

  • Describe chronic liver disease (CLD) management recommendations/guidelines for new treatments

  • Optimize treatment results for patients with CLD, through utilizing new therapies

  • Identify new advances presented at 2021 AASLD and assess their potential impact on clinical practice

Credit Designation

 This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of the Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Southern California Society of Gastroenterology (SCSG).  RMCHCS is accredited by NMMS to provide continuing medical education for physicians.


RMCHCS designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. 

MOC Designation:

Successful completion of this CME activity enables the participant to earn up to 7.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.


The Liver Symposium Co-Chair Committee

Steven-Huy Han, MD

Paul Pockros, MD

Jeffrey Kahn, MD

This activity is supported by educational grants from Gilead Sciences, Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.